Aridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumonia

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


Aridis Pharmaceuticals (NASDAQ:ARDS) monoclonal antibody therapy AR-301 failed the main goal in a phase 3 trial to treat Ventilator Associated Pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).

The study, dubbed AR-301-002, evaluated the superiority of adjunctive use of AR-301 with standard of

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!